POSA370 Healthcare Resource Use By European Patients Enrolled in RA-be-Real: A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease Modifying Therapies

Abstract

Baricitinib (BARI) is a JAK1/2 inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). RA-BE-REAL is a 3-year, prospective, observational study of adult RA patients (pts). The overall study Objectives: are to report the proportion of pts that discontinue treatment and to report the extent of healthcare resource use (HRU) by pts following 6-months (M) of either BARI, biologic (b)DMARDs or any other targeted synthetic (ts)DMARDs (b/tsDMARDs) after starting that treatment for the first time.